Treatment of chronic hepatitis C with recombinant interferon alfa-2b.
In a study of 87 patients with chronic hepatitis C, 12 months' treatment with interferon alfa-2b at a dose of 6 million units (MU) three times per week seemed to be more effective than treatment with 3 MU three times a week for two months plus 1.5 MU three times a week for 10 months in increasing the percentage of long term responders. The percentage of patients in whom alanine amino-transferase activities returned to normal was highest in the 6 MU group, as was the percentage of responders who sustained this normal activity after treatment. Side effects were moderate and self-limited in most patients.
Piazza
M
M
Department of Infectious Diseases, II Medical School, University of Naples, Italy.
Orlando
R
R
Tosone
G
G
Tiseo
D
D
Conte
M C
MC
Minervini
F
F
Santoro
G
G
Scordino
F
F
Vitale
D
D
D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D006526:Hepatitis C / Q000201:enzymology / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000628:therapy*; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000410:Alanine Transaminase